Indication: Relapsed or Refractory Diffuse Large B-Cell Lympho
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of
Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Merck & Co., Inc